Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR402663 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I - SAR402663 open-label (OL) | EXPERIMENTAL | Participants will receive a single dose of SAR402663 on Day 1. Multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants. |
| Part II - SAR402663 Dose A | EXPERIMENTAL | Participants will receive a single dose of SAR402663 on Day 1. |
| Part II - SAR402663 Dose B | EXPERIMENTAL | Participants will receive a single dose of SAR402663 on Day 1. |
| Name | Type | Description |
|---|---|---|
| SAR402663 | BIOLOGICAL | Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection |
| Diluent | DRUG | Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection |
Inclusion Criteria: * Between 50 and 90 years of age * Participants with diagnosis of macular neovascularization secondary to age-related macular degeneration (nAMD) * Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for dose escalation (Part I) between 20/32 and 20/400 a...
SAR402663 is an investigational monoclonal antibody being developed for neovascular age-related macular degeneration, a condition that causes abnormal blood vessel growth and vision loss. It is administered as a one-time treatment in adults with this condition. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SAR402663 is a monoclonal antibody, but its specific molecular target has not been disclosed in available clinical trial information. The drug is being studied for its safety and efficacy in treating neovascular age-related macular degeneration, a disease characterized by abnormal blood vessel growth in the eye. Further research is needed to clarify its mechanism of action.
SAR402663 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of neovascular age-related macular degeneration.
SAR402663 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies for commercial use. The ongoing Phase 1 trial is designed to assess the safety and efficacy of a one-time administration of SAR402663 in adults with neovascular age-related macular degeneration.
SAR402663 is being evaluated in a Phase 1 clinical trial registered as NCT06660667. This study is a randomized, double-blind, controlled trial involving 66 participants with neovascular age-related macular degeneration. The trial is active but not recruiting participants and is being conducted in the United States and United Kingdom.